Sushmita Panda's profile photo

Sushmita Panda

Delhi, New Delhi

Pharma Reporter at Citeline

Pharma Reporter @PharmaScrip, @Citeline | Potterhead | Bibliophile | Alum: @acjindia | tip/lead: [email protected]

Featured in: Favicon financialexpress.com Favicon msn.com Favicon sputniknews.com Favicon indiatvnews.com Favicon spacedaily.com Favicon einnews.com Favicon sundayguardianlive.com Favicon thedailyguardian.com Favicon yerepouni-news.com Favicon informa.com

Articles

  • In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

    1 week ago | insights.citeline.com | Sushmita Panda

    In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck CancerUS FDA Meeting RequestedAustralian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval. Immutep said it will meet with regulators to discuss next steps after strong OS data for combo therapy in 1L HNSCC. (Shutterstock)

  • In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

    1 week ago | insights.citeline.com | Sushmita Panda

    In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AMLMutation-Agnostic Treatment Advances Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia. Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients. (Shutterstock)

  • In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

    1 week ago | insights.citeline.com | Sushmita Panda

    In Brief: Genmab To Seek FDA Nod For Epkinly In LymphomaGenmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

  • In Brief: Sanofi Gains €10bn From Opella Sale

    2 weeks ago | insights.citeline.com | Sushmita Panda

    In Brief: Sanofi Gains €10bn From Opella Sale Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

  • In Brief: Merck To Invest $1bn In New US Biologics Production

    2 weeks ago | insights.citeline.com | Sushmita Panda

    In Brief: Merck To Invest $1bn In New US Biologics ProductionMerck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns. Merck faces heightened tariff risk. (Shutterstock)

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
4K
Tweets
8K
DMs Open
Yes
Sushmita Panda
Sushmita Panda @SushmitaPanda
9 May 25

RT @anantgoenka: It's tough not to watch TV at a time like this, but after last night I strongly suggest: don't.

Sushmita Panda
Sushmita Panda @SushmitaPanda
8 May 25

RT @Citeline: #CitelineElevateSpring25 has begun in style with an opening address from Claire Riches, VP Clinical Solutions at Citeline! We…

Sushmita Panda
Sushmita Panda @SushmitaPanda
30 Apr 25

RT @QuoteNietzsche: Have you read Camus and felt like he’s speaking directly to your soul? https://t.co/plIrLYMPUn